Although this region can be amplified directly leading to 1q+, in addition it can be translocated into a number of receptor chromosomal regions. These translocations lead to gain of 1q, located on the receptor chromosome, but can also lead to loss of genetic material, potentially leading to the deregulation of genes at the receptor site. They show that this mechanism can deregulate MYC, BCL2, FGFR3, CYLD, and WWOX, all of which are genes relevant to the myeloma. They also define an important new mechanism based on JTT1q12 whereby multiple regions of the genome can be deregulated by a single mechanism. The new pathologic mechanism involves sequential translocations of the J TT1q12 from one receptor chromosome to another, which at the same time leads to amplification of regions from the original receptor chromosome, which become part of the second translocation. Thus, it appears that these jumping translocations can lead to both amplification and deletions of interstitial chromosomal regions throughout the genome. This mechanism, when combined with the Darwinian outgrowth of subclones, with a growth advantage, based on deregulation of myeloma specific genes, could lead to progression via a myeloma-specific mechanism. In this respect, they also go on to define a specific association of JTT1q12 with 17p−, the site of the P53 gene, an important negative prognostic factor in myeloma. Extending this observation further, they describe in 6 of 14 patients with t(4;14) the role of JTT1q12 as a mechanism leading to 17p−. This observation implicates a specific mechanism driven via JTT1q12, active in t(4;4) myeloma, which mediates rapid progression of the disease from standard to high-risk disease. Using this mechanism as an example, they also confirm the importance of clonal selection leading to clonal predominance as being the mechanism underlying disease progression.

Conflict-of-interest disclosure: The author declares no competing financial interests.

REFERENCES

© 2014 by The American Society of Hematology

Comment on Kobayashi et al, page 2540

Novel signaling axis in CML-initiating cells

Cheng Cheng Zhang1 UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER

In this issue of Blood, Kobayashi et al demonstrate that CD25, the α-chain of the interleukin-2 receptor (IL-2RA), is expressed by certain cells that initiate chronic myeloid leukemia (CML) in a mouse model and that the IL-2/CD25 signaling axis supports CML development.1

CML is a hematopoietic malignancy that results from the t(9;22)(q34;q11) chromosome translocation, which produces the BCR/ABL fusion oncogene. Tyrosine kinase inhibitors (TKIs) effectively treat the BCR/ABL fusion oncogene. Tyrosine kinase inhibitors (TKIs) effectively treat symptoms. It was proposed that leukemia-initiating cells (LICs) in these patients are insensitive to TKIs.2 Although CML LICs are thought to be CD138− and CD38− cells and its expression positively correlated with disease progression based on an in silico analysis.

The new findings of Kobayashi et al have important biological implications. Consistent with the roles of other signaling pathways, including Wnt/β-catenin, Hedgehog, and IL-6,3,4 this study suggests that certain signalings that are dispensable in normal HSCs are activated in leukemia stem cells. Such signaling pathways may contribute to cancer initiation or progression and provide targets for therapeutics designed to eliminate cancer. Importantly, the study by Kobayashi et al revealed a novel, unique relationship between the niche and CML LICs mediated through the IL-2/CD25
Proposed model indicating that distinct subsets of CML LICs are supported by the IL-2/CD25 axis. Both CD25<sup>+</sup> FcγRIIa<sup>−</sup> Lin<sup>−</sup> Sca-1<sup>−</sup> c-Kit<sup>−</sup> (F<sup>−</sup> LSK) cells and CD25<sup>−</sup> F<sup>−</sup> LSK cells possess CML LIC activities and can interconvert each other. CD25<sup>−</sup> F<sup>−</sup> LSK cells are also capable of differentiating into mast cells, and cycle faster than the CD25<sup>+</sup> counterpart. Microenvironment produced IL-2 can act on CD25<sup>−</sup> F<sup>−</sup> LSK cells, which further produce TGF-β to support self-renewal of both CD25<sup>−</sup> and CD25<sup>+</sup> CML LICs. See supplemental Figure 16 in the article by Kobayashi et al that begins on page 2540.

signaling axis. Their analysis also indicates that the surface phenotype of CML LICs differs from that of normal HSCs, and suggests that CML LICs can be further purified. Furthermore, the authors showed that CML LICs contain both CD25<sup>−</sup> and CD25<sup>+</sup> fractions. This is concordant with the suggestion that distinct populations of cancer stem cells may be able to exist in a single patient that enable the tumor to evolve in order to adapt to the dynamic tumor microenvironment.3

This study raises provocative questions regarding extrinsic signaling for leukemia stem cells. It was known that the signal transducer and activator of transcription (STAT) pathway is activated by BCR/ABL and that Janus kinase/STAT signaling is the pathway activated by cytokine receptors including IL-2R.3 Is IL-2/CD25 signaling in CML LICs independent of BCR/ABL-induced signaling? How does this axis, together with other extrinsic and intrinsic pathways (IL-6, Wnt, Hedgehog, bone morphogenetic proteins, selectin and ligands, transforming growth factor-β[TGF-β], Alox3, among others),5,6,8 regulate the cell fates of CML LICs such as self-renewal, differentiation, apoptosis, and migration? What are the IL-2<sup>+</sup> niche cells and how do these cells contribute to the complex nature of the CML LIC niche? Given extensive aberrant signaling in CML cells, is it possible to cure CML by combined use of TKIs and inhibition of a limited number of key extrinsic pathways? Because CD25 is considered as a prognostic factor for the acute myeloid leukemia (AML) development,9,10 might the IL-2/CD25 axis be a niche signaling in other hematopoietic malignancies including AML?

An important clinically relevant question is whether CD25 is a marker for human CML LICs and what human population is the counterpart of mouse CD25<sup>+</sup> F<sup>−</sup> LSK cells. The authors of the current study showed that CD25 expression is higher in the accelerated phase (AP) and even further increased in the blast crisis (BC) phase of human CML than in the chronic phase (Figure 6E, Kobayashi et al). Because the myeloid BC in CML resembles AML, and CD25 is also considered a prognostic factor for AML development,9,10 an interesting hypothesis triggered by these observations is that CD25 may mark or promote human CML advancement in the AP or BC stage. If so, the IL-2/CD25 axis may not regulate the initiation of human CML but may contribute to disease progression. Testing this hypothesis may shed light on the pathobiology of the currently intractable AP and early phase of BC of CML.6

Overall, Kobayashi et al demonstrate that the IL-2/CD25 signaling axis is a promising antileukemia target that is activated in CML LICs, but not in normal HSCs. Inhibition of the IL-2/CD25 axis may contribute to the development of future combination therapies that selectively target multiple key signaling pathways unique to CML LICs and ultimately eradicate CML.

Conflict-of-interest disclosure: The author declares no competing financial interests.

REFERENCES
Novel signaling axis in CML-initiating cells

Cheng Cheng Zhang